| Style | Citing Format |
|---|---|
| MLA | Yeh WZ, et al.. "Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies." Neurology: Neuroimmunology and NeuroInflammation, vol. 11, no. 6, 2024, pp. -. |
| APA | Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabispedrini MJ, Carroll WM, Lechnerscott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, ... Cardenasrobledo S (2024). Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation, 11(6), -. |
| Chicago | Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabispedrini MJ, et al.. "Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies." Neurology: Neuroimmunology and NeuroInflammation 11, no. 6 (2024): -. |
| Harvard | Yeh WZ et al. (2024) 'Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies', Neurology: Neuroimmunology and NeuroInflammation, 11(6), pp. -. |
| Vancouver | Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, et al.. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. 2024;11(6):-. |
| BibTex | @article{ author = {Yeh WZ and Van Der Walt A and Skibina OG and Kalincik T and Alroughani R and Kermode AG and Fabispedrini MJ and Carroll WM and Lechnerscott J and Boz C and Ozakbas S and Buzzard K and Habek M and John NA and Prat A and Girard M and Duquette P and Baghbanian SM and Hodgkinson S and Van Pesch V and Laureys G and Willekens B and Prevost J and Foschi M and De Gans K and Horakova D and Havrdova EK and Karabudak R and Patti F and Mccombe PA and Maimone D and Altintas A and Ampapa R and Spitaleri D and Gerlach OHH and Sa MJ and Hughes S and Gouider R and Mrabet S and Macdonell RA and Turkoglu R and Cartechini E and Alasmi A and Soysal A and Oh J and Murosle Rouzic E and Guye S and Pasquarelli N and Butzkueven H and Jokubaitis VG and Barnett M and Slee M and Van Hijfte L and Yamout B and Terzi M and Blanco Y and Grammond P and Izquierdo G and Besora S and Taylor B and Castillotrivino T and Sanchezmenoyo JL and Lugaresi A and Amato MP and Hardy T and Decoo D and Fragoso Y and Iuliano G and Gray O and Saladino ML and Grandmaison F and Sempere AP and Shaw C and Van Wijmeersch B and Csepany T and Solaro C and Alkhaboori J and Garber J and Dominguez JA and Piroska I and Mcguigan C and Cauchi M and Skromne E and Trevinofrenk I and Mason D and Sirbu CA and Etemadifar M and Nohara C and Cambron M and De Vecino MCA and Shalaby N and Field D and Agueramorales E and Khurana D and Matsumoto R and Shimizu F and Sinnige LGF and Cardenasrobledo S}, title = {Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies}, journal = {Neurology: Neuroimmunology and NeuroInflammation}, volume = {11}, number = {6}, pages = {-}, year = {2024} } |
| RIS | TY - JOUR AU - Yeh WZ AU - Van Der Walt A AU - Skibina OG AU - Kalincik T AU - Alroughani R AU - Kermode AG AU - Fabispedrini MJ AU - Carroll WM AU - Lechnerscott J AU - Boz C AU - Ozakbas S AU - Buzzard K AU - Habek M AU - John NA AU - Prat A AU - Girard M AU - Duquette P AU - Baghbanian SM AU - Hodgkinson S AU - Van Pesch V AU - Laureys G AU - Willekens B AU - Prevost J AU - Foschi M AU - De Gans K AU - Horakova D AU - Havrdova EK AU - Karabudak R AU - Patti F AU - Mccombe PA AU - Maimone D AU - Altintas A AU - Ampapa R AU - Spitaleri D AU - Gerlach OHH AU - Sa MJ AU - Hughes S AU - Gouider R AU - Mrabet S AU - Macdonell RA AU - Turkoglu R AU - Cartechini E AU - Alasmi A AU - Soysal A AU - Oh J AU - Murosle Rouzic E AU - Guye S AU - Pasquarelli N AU - Butzkueven H AU - Jokubaitis VG AU - Barnett M AU - Slee M AU - Van Hijfte L AU - Yamout B AU - Terzi M AU - Blanco Y AU - Grammond P AU - Izquierdo G AU - Besora S AU - Taylor B AU - Castillotrivino T AU - Sanchezmenoyo JL AU - Lugaresi A AU - Amato MP AU - Hardy T AU - Decoo D AU - Fragoso Y AU - Iuliano G AU - Gray O AU - Saladino ML AU - Grandmaison F AU - Sempere AP AU - Shaw C AU - Van Wijmeersch B AU - Csepany T AU - Solaro C AU - Alkhaboori J AU - Garber J AU - Dominguez JA AU - Piroska I AU - Mcguigan C AU - Cauchi M AU - Skromne E AU - Trevinofrenk I AU - Mason D AU - Sirbu CA AU - Etemadifar M AU - Nohara C AU - Cambron M AU - De Vecino MCA AU - Shalaby N AU - Field D AU - Agueramorales E AU - Khurana D AU - Matsumoto R AU - Shimizu F AU - Sinnige LGF AU - Cardenasrobledo S TI - Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies JO - Neurology: Neuroimmunology and NeuroInflammation VL - 11 IS - 6 SP - EP - PY - 2024 ER - |